About Enhancer
| Enhancer ID: | E_01_0489 |
| Species: | human |
| Position : | chr12:47838311-47840311   |
| Biosample name: | |
| Experiment class : | High+Lowthroughput |
| Enhancer type: | Enhancer |
| Disease: | Type 2 diabetes (t2d) |
| Pubmed ID: | 29754817 |
| Enhancer experiment: | CRISPR screening,RNA-Seq,qPCR,H&E staining,Immunohistochemistry,immunofluorescence,Immunoprecipitation,siRNA knockdown,transfection,shRNA knockdown,FACS analysis,ELISA,Chromatin Immunoprecipitation,ChIP-Seq,ATAC-Seq,Transmission electronic microscopy,LC-MS Analysis, |
| Enhancer experiment description: | Mechanistically, ligand promotes VDR association with PBAF to effect genome-wide changes in chromatin accessibility and enhancer landscape, resulting in an anti-inflammatory response. Importantly, pharmacological inhibition of BRD9 promotes PBAF-VDR association to restore ? cell function and ameliorate hyperglycemia in murine T2D models. These studies reveal an unrecognized VDR-dependent transcriptional program underpinning ? cell survival and identifies the VDR:PBAF/BAF association as a potential therapeutic target for T2D. |
About Target gene
| Target gene : | BRD7,BRD9 |
| Strong evidence: | qRT-PCR,qPCR,ChIP,3C |
| Less strong evidence: | RNA-Seq |
| Target gene experiment description: | Mechanistically, ligand promotes VDR association with PBAF to effect genome-wide changes in chromatin accessibility and enhancer landscape, resulting in an anti-inflammatory response. Importantly, pharmacological inhibition of BRD9 promotes PBAF-VDR association to restore ? cell function and ameliorate hyperglycemia in murine T2D models. These studies reveal an unrecognized VDR-dependent transcriptional program underpinning ? cell survival and identifies the VDR:PBAF/BAF association as a potential therapeutic target for T2D.;Mechanistically, ligand promotes VDR association with PBAF to effect genome-wide changes in chromatin accessibility and enhancer landscape, resulting in an anti-inflammatory response. Importantly, pharmacological inhibition of BRD9 promotes PBAF-VDR association to restore ? cell function and ameliorate hyperglycemia in murine T2D models. These studies reveal an unrecognized VDR-dependent transcriptional program underpinning ? cell survival and identifies the VDR:PBAF/BAF association as a potential therapeutic target for T2D.;Mechanistically, ligand promotes VDR association with PBAF to effect genome-wide changes in chromatin accessibility and enhancer landscape, resulting in an anti-inflammatory response. Importantly, pharmacological inhibition of BRD9 promotes PBAF-VDR association to restore ? cell function and ameliorate hyperglycemia in murine T2D models. These studies reveal an unrecognized VDR-dependent transcriptional program underpinning ? cell survival and identifies the VDR:PBAF/BAF association as a potential therapeutic target for T2D. |
About TF
| TF name : | CYP27B1 |
| TF experiment: | CRISPR screening,RNA-Seq,qPCR,H&E staining,Immunohistochemistry,immunofluorescence,Immunoprecipitation,siRNA knockdown,transfection,shRNA knockdown,FACS analysis,ELISA,Chromatin Immunoprecipitation,ChIP-Seq,ATAC-Seq,Transmission electronic microscopy,LC-MS Analysis, |
| TF experiment description: | Mechanistically, ligand promotes VDR association with PBAF to effect genome-wide changes in chromatin accessibility and enhancer landscape, resulting in an anti-inflammatory response. Importantly, pharmacological inhibition of BRD9 promotes PBAF-VDR association to restore ? cell function and ameliorate hyperglycemia in murine T2D models. These studies reveal an unrecognized VDR-dependent transcriptional program underpinning ? cell survival and identifies the VDR:PBAF/BAF association as a potential therapeutic target for T2D.;Mechanistically, ligand promotes VDR association with PBAF to effect genome-wide changes in chromatin accessibility and enhancer landscape, resulting in an anti-inflammatory response. Importantly, pharmacological inhibition of BRD9 promotes PBAF-VDR association to restore ? cell function and ameliorate hyperglycemia in murine T2D models. These studies reveal an unrecognized VDR-dependent transcriptional program underpinning ? cell survival and identifies the VDR:PBAF/BAF association as a potential therapeutic target for T2D.;Mechanistically, ligand promotes VDR association with PBAF to effect genome-wide changes in chromatin accessibility and enhancer landscape, resulting in an anti-inflammatory response. Importantly, pharmacological inhibition of BRD9 promotes PBAF-VDR association to restore ? cell function and ameliorate hyperglycemia in murine T2D models. These studies reveal an unrecognized VDR-dependent transcriptional program underpinning ? cell survival and identifies the VDR:PBAF/BAF association as a potential therapeutic target for T2D. |
About Function
| Enhancer function : | Mechanistically, ligand promotes VDR association with PBAF to effect genome-wide changes in chromatin accessibility and enhancer landscape, resulting in an anti-inflammatory response. Importantly, pharmacological inhibition of BRD9 promotes PBAF-VDR association to restore ? cell function and ameliorate hyperglycemia in murine T2D models. These studies reveal an unrecognized VDR-dependent transcriptional program underpinning ? cell survival and identifies the VDR:PBAF/BAF association as a potential therapeutic target for T2D. |
| Enhancer function experiment: | Immunohistochemical staining |
| Enhancer function experiment description: |
Mechanistically, ligand promotes VDR association with PBAF to effect genome-wide changes in chromatin accessibility and enhancer landscape, resulting in an anti-inflammatory response. Importantly, pharmacological inhibition of BRD9 promotes PBAF-VDR association to restore ? cell function and ameliorate hyperglycemia in murine T2D models. These studies reveal an unrecognized VDR-dependent transcriptional program underpinning ? cell survival and identifies the VDR:PBAF/BAF association as a potential therapeutic target for T2D. |
About SNP
| SNP ID: | -- |
Upstream Pathway Annotation of TF
| GeneName | Pathway Name | Source | Gene Number |
|---|---|---|---|
| CYP27B1 | Vitamin D (calciferol) metabolism | reactome | 7 |
| CYP27B1 | Vitamin D metabolism and pathway | panther | 6 |
| CYP27B1 | Vitamins | reactome | 6 |
| CYP27B1 | Steroid biosynthesis | kegg | 18 |
Enhancer associated network
The number on yellow line represents the distance between enhancer and
target gene